Skip to main content
x

Recent articles

Imfinzi puts its flag on the Matterhorn

A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.

ITM hopes to Compete against Lutathera

The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.

Merck and Sanofi sound the alarm for ILT inhibition

Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.

GSK and Hansoh press on despite Pfizer’s exit

A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.

T-cell engagement with a difference

In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.

Chimerix turns $39m into $935m

The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.